AI Engines For more Details: Perplexity Kagi Labs You
Tuberculosis (TB): Rifapentine is used in the treatment of tuberculosis, particularly drug-sensitive TB and latent TB infection. It is often used as part of combination therapy regimens, especially in the continuation phase of treatment.
Latent Tuberculosis Infection (LTBI): Rifapentine, when used in combination with isoniazid, is approved for the treatment of latent tuberculosis infection in individuals who are at high risk of progression to active TB disease. This treatment regimen is known as the 3HP regimen (3 months of rifapentine and isoniazid).
Mycobacterium leprae Infections: Rifapentine has been used off-label in the treatment of leprosy (Hansen's disease) caused by Mycobacterium leprae. However, its use for this indication may vary depending on local guidelines and practices.
Other Mycobacterial Infections: Rifapentine may also have activity against other mycobacterial infections, although its use for these indications is less common and may vary depending on the specific organism and local resistance patterns.
Side Effects: Common side effects of rifapentine include gastrointestinal disturbances such as nausea, vomiting, diarrhea, and abdominal pain. It may also cause changes in urine color (orange-red), rash, fever, headache, and joint pain. Rifapentine may interact with other medications, including antiretroviral drugs used in the treatment of HIV/AIDS.
Drug Interactions: Rifapentine is a potent inducer of drug-metabolizing enzymes in the liver, particularly cytochrome P450 enzymes. Therefore, it can interact with many medications, including antiretroviral drugs (such as protease inhibitors and non-nucleoside reverse transcriptase inhibitors), antifungal agents, immunosuppressants, and oral contraceptives. Dose adjustments or careful monitoring may be necessary when rifapentine is used concomitantly with other medications.
Pregnancy and Lactation: The safety of rifapentine during pregnancy and lactation has not been well established. It should be used during pregnancy only if the potential benefits outweigh the potential risks. Breastfeeding should be avoided during rifapentine therapy.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| species | Parabacteroides distasonis | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.9 | 0.9 | |
| Acne | 0.3 | -0.3 | |
| ADHD | 5.1 | 0.6 | 7.5 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 3.4 | 3.5 | -0.03 |
| Allergies | 7.5 | 4.3 | 0.74 |
| Allergy to milk products | 2.6 | 1.6 | 0.63 |
| Alopecia (Hair Loss) | 1.6 | 1.6 | |
| Alzheimer's disease | 7.5 | 8.3 | -0.11 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 4.3 | 1.5 | 1.87 |
| Ankylosing spondylitis | 5.3 | 1.8 | 1.94 |
| Anorexia Nervosa | 1.6 | 3.2 | -1 |
| Antiphospholipid syndrome (APS) | 2.1 | 0.3 | 6 |
| Asthma | 6.5 | 3.4 | 0.91 |
| Atherosclerosis | 2.7 | 2.4 | 0.13 |
| Atrial fibrillation | 4.1 | 3.1 | 0.32 |
| Autism | 11.9 | 11.9 | 0 |
| Autoimmune Disease | 1.2 | 1 | 0.2 |
| Barrett esophagus cancer | 0.6 | 0.3 | 1 |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 3 | 3 | |
| Bipolar Disorder | 2.4 | 1.7 | 0.41 |
| Brain Trauma | 0.9 | 1.4 | -0.56 |
| Breast Cancer | 1.2 | 1.2 | |
| Cancer (General) | 0.9 | 3.4 | -2.78 |
| Carcinoma | 4.9 | 2.6 | 0.88 |
| Celiac Disease | 3.6 | 4.3 | -0.19 |
| Cerebral Palsy | 1.9 | 1.3 | 0.46 |
| Chronic Fatigue Syndrome | 6.6 | 7.7 | -0.17 |
| Chronic Kidney Disease | 5.2 | 3.4 | 0.53 |
| Chronic Lyme | 0.6 | 0.8 | -0.33 |
| Chronic Obstructive Pulmonary Disease (COPD) | 3 | 2 | 0.5 |
| Chronic Urticaria (Hives) | 2 | 1.8 | 0.11 |
| Coagulation / Micro clot triggering bacteria | 1.9 | 1.3 | 0.46 |
| Cognitive Function | 3.1 | 1.6 | 0.94 |
| Colorectal Cancer | 8.9 | 2.8 | 2.18 |
| Constipation | 2.1 | 0.7 | 2 |
| Coronary artery disease | 3 | 3 | 0 |
| COVID-19 | 11.9 | 14.7 | -0.24 |
| Crohn's Disease | 10.4 | 6.9 | 0.51 |
| Cushing's Syndrome (hypercortisolism) | 0.9 | -0.9 | |
| cystic fibrosis | 1.2 | 1.9 | -0.58 |
| d-lactic acidosis (one form of brain fog) | 0.6 | 0.6 | |
| deep vein thrombosis | 3.2 | 1.4 | 1.29 |
| Denture Wearers Oral Shifts | 2.1 | 2.1 | |
| Depression | 14 | 11.6 | 0.21 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 2.3 | 2.6 | -0.13 |
| Endometriosis | 3.5 | 2.6 | 0.35 |
| Eosinophilic Esophagitis | 0.3 | 0.6 | -1 |
| Epilepsy | 4.5 | 2.8 | 0.61 |
| erectile dysfunction | 1.4 | 0.3 | 3.67 |
| Fibromyalgia | 3.5 | 2.6 | 0.35 |
| Functional constipation / chronic idiopathic constipation | 6.9 | 4.9 | 0.41 |
| gallstone disease (gsd) | 4.3 | 1.6 | 1.69 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 2.4 | 1.2 | 1 |
| Generalized anxiety disorder | 3.9 | 2.5 | 0.56 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 2.6 | 1 | 1.6 |
| Graves' disease | 1.9 | 3.3 | -0.74 |
| Gulf War Syndrome | 0.9 | 2.6 | -1.89 |
| Halitosis | 1.8 | 0.3 | 5 |
| Hashimoto's thyroiditis | 4.4 | 2.3 | 0.91 |
| Heart Failure | 5.4 | 2.4 | 1.25 |
| hemorrhagic stroke | 1.3 | 1.3 | |
| Hidradenitis Suppurativa | 1.4 | 0.3 | 3.67 |
| High Histamine/low DAO | 1.9 | 0.6 | 2.17 |
| hypercholesterolemia (High Cholesterol) | 1.1 | 0.6 | 0.83 |
| hyperglycemia | 3 | 2.2 | 0.36 |
| Hyperlipidemia (High Blood Fats) | 1.4 | 0.3 | 3.67 |
| hypersomnia | 0.7 | -0.7 | |
| hypertension (High Blood Pressure | 5.8 | 6.8 | -0.17 |
| Hypothyroidism | 0.5 | 1 | -1 |
| Hypoxia | 4.1 | 0.3 | 12.67 |
| IgA nephropathy (IgAN) | 1.9 | 5.5 | -1.89 |
| Inflammatory Bowel Disease | 10.8 | 12.1 | -0.12 |
| Insomnia | 2.5 | 3.5 | -0.4 |
| Intelligence | 2 | 0.6 | 2.33 |
| Intracranial aneurysms | 1.4 | 0.6 | 1.33 |
| Irritable Bowel Syndrome | 10 | 6.4 | 0.56 |
| ischemic stroke | 3.2 | 1.7 | 0.88 |
| Liver Cirrhosis | 9.2 | 5.9 | 0.56 |
| Long COVID | 8.6 | 9.3 | -0.08 |
| Low bone mineral density | 1.1 | -1.1 | |
| Lung Cancer | 1.5 | 1.6 | -0.07 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 1.5 | 0.9 | 0.67 |
| ME/CFS with IBS | 1.1 | 2.4 | -1.18 |
| ME/CFS without IBS | 2 | 2.4 | -0.2 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 2.1 | 1 | 1.1 |
| Metabolic Syndrome | 9.5 | 9.6 | -0.01 |
| Mood Disorders | 14 | 9.5 | 0.47 |
| multiple chemical sensitivity [MCS] | 1.7 | 0.1 | 16 |
| Multiple Sclerosis | 9 | 7 | 0.29 |
| Multiple system atrophy (MSA) | 2.3 | 0.7 | 2.29 |
| myasthenia gravis | 0.9 | 0.7 | 0.29 |
| neuropathic pain | 0.3 | 3.6 | -11 |
| Neuropathy (all types) | 1.2 | 2.2 | -0.83 |
| neuropsychiatric disorders (PANDAS, PANS) | 1.2 | 1.2 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 6.3 | 5.9 | 0.07 |
| NonCeliac Gluten Sensitivity | 1.9 | 0.6 | 2.17 |
| Obesity | 12.8 | 10.6 | 0.21 |
| obsessive-compulsive disorder | 7 | 4.8 | 0.46 |
| Osteoarthritis | 3.1 | 1.7 | 0.82 |
| Osteoporosis | 2.5 | 1.9 | 0.32 |
| pancreatic cancer | 1.2 | 0.3 | 3 |
| Parkinson's Disease | 10.6 | 8.1 | 0.31 |
| Polycystic ovary syndrome | 7.9 | 3.7 | 1.14 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.6 | -2 |
| Premenstrual dysphoric disorder | 0.7 | 0.4 | 0.75 |
| primary biliary cholangitis | 1.2 | 1.7 | -0.42 |
| Primary sclerosing cholangitis | 3 | 3.2 | -0.07 |
| Psoriasis | 4.4 | 4 | 0.1 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 9.6 | 4.7 | 1.04 |
| Rosacea | 1.2 | 0.7 | 0.71 |
| Schizophrenia | 7.8 | 3.6 | 1.17 |
| scoliosis | 0.9 | 1.2 | -0.33 |
| Sjögren syndrome | 3.2 | 3.2 | 0 |
| Sleep Apnea | 2.2 | 1.8 | 0.22 |
| Slow gastric motility / Gastroparesis | 1.5 | 0.3 | 4 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 2.2 | 0.6 | 2.67 |
| Stress / posttraumatic stress disorder | 3.7 | 3.3 | 0.12 |
| Systemic Lupus Erythematosus | 4.9 | 2.4 | 1.04 |
| Tic Disorder | 1.5 | 1.8 | -0.2 |
| Tourette syndrome | 1.4 | 0.3 | 3.67 |
| Type 1 Diabetes | 5.1 | 4.4 | 0.16 |
| Type 2 Diabetes | 10.5 | 9 | 0.17 |
| Ulcerative colitis | 6.8 | 8.8 | -0.29 |
| Unhealthy Ageing | 6.8 | 2.9 | 1.34 |
| Vitiligo | 2.5 | 2 | 0.25 |
